BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+23.73%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$8.79B
AUM Growth
+$8.79B
(-49%)
Cap. Flow
-$9.7B
Cap. Flow
% of AUM
-110.42%
Top 10 Holdings %
Top 10 Hldgs %
80.97%
Holding
105
New
4
Increased
23
Reduced
13
Closed
21
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$159M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$98.3M |
| 3 |
Revolution Medicines
RVMD
|
$70.5M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$67.8M |
| 5 |
Replimune Group
REPL
|
$41.9M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$9.45B |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$337M |
| 3 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$198M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$69.4M |
| 5 |
Roivant Sciences
ROIV
|
$48.1M |
Sector Composition
| 1 | Healthcare | 98.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Incyte
INCY
$16.5B
| $2.27B | 25.85% | 36,179,122 +556 | +0% | +$34.9K |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.91B | 21.69% | 10,568,897 -1,100,000 | -9% | -$198M |
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $1.34B | 15.27% | 42,864,612 | – | – |
|
|
4
Madrigal Pharmaceuticals
MDGL
$9.76B
| $456M | 5.19% | 1,969,798 +424,685 | +27% | +$98.3M |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $294M | 3.35% | 6,398,365 -303,984 | -5% | -$14M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $242M | 2.76% | 4,121,440 +2,711,656 | +192% | +$159M |
|
7
Immunocore
IMCR
$1.62B
| $172M | 1.96% | 2,520,731 | – | – |
|
8
Kymera Therapeutics
KYMR
$2.95B
| $153M | 1.74% | 5,995,928 +1,245,528 | +26% | +$31.7M |
|
|
9
Revolution Medicines
RVMD
$7.1B
| $148M | 1.68% | 5,148,657 +2,457,164 | +91% | +$70.5M |
|
10
AbCellera Biologics
ABCL
$1.25B
| $131M | 1.49% | 22,909,753 +2,146,430 | +10% | +$12.3M |
|
|
11
Roivant Sciences
ROIV
$8.15B
| $85.3M | 0.97% | 7,593,024 -4,284,147 | -36% | -$48.1M |
|
|
12
Replimune Group
REPL
$422M
| $80.5M | 0.92% | 9,545,336 +4,967,056 | +108% | +$41.9M |
|
13
Entrada Therapeutics
TRDA
$208M
| $73.4M | 0.84% | 4,865,819 | – | – |
|
14
Ultragenyx Pharmaceutical
RARE
$2.89B
| $70.1M | 0.8% | 1,466,547 +100,000 | +7% | +$4.78M |
|
|
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $67.8M | 0.77% | +1,600,000 | New | +$67.8M |
|
16
Immatics
IMTX
$619M
| $61.5M | 0.7% | 5,838,853 +198,037 | +4% | +$2.09M |
|
17
BioCryst Pharmaceuticals
BCRX
$1.74B
| $60.7M | 0.69% | 10,126,176 -2,584,642 | -20% | -$15.5M |
|
18
argenx
ARGX
$43.6B
| $57.5M | 0.65% | 151,215 | – | – |
|
19
Denali Therapeutics
DNLI
$2.23B
| $56M | 0.64% | 2,607,196 +315,193 | +14% | +$6.76M |
|
20
Akero Therapeutics
AKRO
$3.74B
| $55.3M | 0.63% | 2,368,378 | – | – |
|
21
Kodiak Sciences
KOD
$478M
| $52.6M | 0.6% | 17,310,490 | – | – |
|
22
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $49.3M | 0.56% | 2,809,577 | – | – |
|
23
Xenon Pharmaceuticals
XENE
$2.98B
| $45.8M | 0.52% | 993,679 +242,040 | +32% | +$11.1M |
|
24
Prelude Therapeutics
PRLD
$68.5M
| $43.2M | 0.49% | 10,123,824 | – | – |
|
25
Cerus
CERS
$251M
| $42.1M | 0.48% | 19,477,339 +2,237,838 | +13% | +$4.83M |
|